Genome editing of human Tregs to enable combinational tolerogenic therapy with T cell-targeted biologics for T1D

  • Post author:
  • Post category:

Research Objective Genome-edited autologous regulatory T cells for promoting immune tolerance in combination with T-cell-targeting therapies Impact We focus on type 1 diabetes in this proof-of-concept study, but the therapeutic…

Continue ReadingGenome editing of human Tregs to enable combinational tolerogenic therapy with T cell-targeted biologics for T1D

Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients

  • Post author:
  • Post category:

Research Objective We will generate nanoprobe-containing stem cell-derived human beta cells that can be monitored in real time in response to inflammatory stress upon transplantation in patients with type 1…

Continue ReadingBioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients

Extending Immune-Evasive Human Islet-Like Organoids (HILOs) Survival and Function as a Cure for T1D

  • Post author:
  • Post category:

Research Objective Determine optimal islet transplant conditions and systemic treatments that promote graft survival upon transplantation into immune-competent diabetic subjects. Impact Our proposal will optimize the generation and viability of…

Continue ReadingExtending Immune-Evasive Human Islet-Like Organoids (HILOs) Survival and Function as a Cure for T1D

Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes

  • Post author:
  • Post category:

Research Objective Functional human islet like organoids differentiated from human pluripotent stem cells. Impact Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients. Major Proposed Activities Fabrication…

Continue ReadingDual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes

Development of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs

  • Post author:
  • Post category:

Research Objective Development of hESC-derived pancreatic beta cells that are protected from allogeneic and autoimmune attack into a cell therapy for type 1 diabetes (T1D) Impact Cell therapy of T1D…

Continue ReadingDevelopment of immune invisible beta cells as a cell therapy for type 1 diabetes through genetic modification of hESCs